9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To evaluate the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin added to metformin for 12 weeks in patients with type 2 diabetes.

          Related collections

          Author and article information

          Journal
          Diabetes Obes Metab
          Diabetes, obesity & metabolism
          1463-1326
          1462-8902
          Dec 2013
          : 15
          : 12
          Affiliations
          [1 ] Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA.
          Article
          10.1111/dom.12185
          23906374
          1efeeaf2-afce-47d1-8ba6-b6631fdd765a
          © 2013 John Wiley & Sons Ltd.
          History

          HbA1c,SGLT2 inhibitor,add-on therapy,blood pressure,body weight,empagliflozin,tolerability

          Comments

          Comment on this article